Zura Bio Limited · NASDAQ:ZURA
Zura Bio — SPAC Merger (June 2022)
30 slides from Zura Bio's SPAC merger presentation, Jun 17, 2022
Slide 1: Corporate overview June 2022
Strictly private and confidential Corporate overview June 2022
Slide 2: Disclaimer (1/2)
Strictly private and confidential 2 Disclaimer (1/2) ABOUT THIS PRESENTATION This investor presentation (“Presentation”) contains proprietary and confidential information of JATT Acquisition Corp (“JATT ”) and Zura Bio Limited (the “Company”), and the entire content should be considered “Confidentia
Slide 3: Use of Projections and Additional Information
Strictly private and confidential USE OF PROJECTIONS This Presentation contains financial forecasts or projections with respect to JATT and the Company. Neither JATT’s nor the Co mpa ny’s independent auditors have audited, studied, reviewed, compiled or performed any procedures with respect to the p
Slide 4: Zura Bio: clinical-stage biotech focused on novel medicines for immune disorders
Strictly private and confidential Zura Bio: clinical - stage biotech focused on developing novel medicines for immune disorders 1. Interleukin 7 receptor alpha; 2. Interleukin 7; 3. Thymic stromal lymphopoietin 4 ZB - 168: a fully human, anti - IL7R α 1 antibody originally developed by Pfizer • IL7R
Slide 5: The Zura Bio + JATT combination will provide strategic capital for an ambitious development plan
Strictly private and confidential 1. DOI: 10.1038/s41467 - 018 - 06804 - y; 2. DOI: 10.1016/j.alit.2020.01.001; 3. DOI: 10.3389/fimmu.2020.01557/full; 4. Chronic Spontaneous Urticaria ; 5. Chronic obstructive pulmonary disease The Zura Bio + JATT combination will provide strategic capital for an amb
Slide 6: IL7Rα: A unique target for modulating two key immune pathways
Strictly private and confidential 6 IL7R α : A unique target for modulating two key immune pathways ZB - 168 has potential to treat diseases driven by IL7 or TSLP signaling IL7R α JAK1 JAK2 γ c TSLPR IL7R α IL7R α IL7 TSLP JAK3 IL7 is a critical modulator of T - cell homeostasis, proliferation, and
Slide 7: Broad development potential for ZB-168 across Th1, Th17 and Th2 diseases
Strictly private and confidential 7 IL7R/TSLPR ZB - 168 IL7R α Th1/Th17: IL7 signaling Th2: TSLP signaling • Alopecia areata • Type 1 diabetes mellitus • Ulcerative colitis • Sjogren's syndrome • Vitiligo • Asthma • EOE 3 • COPD • CRSwNP 4 • CSU T effector cells T reg cells Mast cells Dendritic cell
Slide 8: IL7R and TSLP are linked to numerous immune diseases with a significant global market potential
Strictly private and confidential IL7R and TSLP are linked to numerous immune diseases with a significant global market potential 8 Total patients ~150M Total addressable market potential 1 >$100B Prevalence (~M) 1. Estimated as of 2025 ~150 7 2 80 25 1 5 2 2 22
Slide 9: Zura Bio and JATT to form an experienced and lean leadership team (I)
Strictly private and confidential Zura Bio and JATT to form an experienced and lean leadership team (I) 9 Leadership team *Someit Sidhu, BM BCh Chief Executive Officer *Javier Cote Sierra, PhD Chief Scientific Officer • NIH academic turned pharma industry veteran • Director of JATT Acquisition Corp
Slide 10: Zura Bio and JATT to form an experienced and lean leadership team (II)
Strictly private and confidential Zura Bio and JATT to form an experienced and lean leadership team (II) 10 Key team members Deb Nevin Manufacturing Lead (consultant) *Harjit Singh Clinical Operations (consultant) Marlyn Mathew Vice President, Finance and Accounting Dave Brady Head of Business Devel
Slide 11: ZB-168 only asset in class pursuing alopecia areata
Strictly private and confidential ZB - 168 only asset in class pursuing alopecia areata 11 ZB - 168 ADX - 914 OSE - 127 GSK2618960 Tezepelumab UPB - 101 Type of antibody Human Human Humanised Humanised Human Human Target IL7R α IL7R α IL7R α IL7R α TSLP TSLPR 1 Mode of administration SC 2 SC IV 3 IV
Slide 12: ZB-168 has the potential to be the first precision medicine treatment for alopecia areata
Strictly private and confidential ZB - 168 has the potential to be the first precision medicine treatment for alopecia areata • Highly prevalent disease, affecting ~700k 1 people in the US • Only one treatment approved for severe alopecia areata, with boxed warnings • Three JAK inhibitors in total a
Slide 13: Multiple read outs expected in 2023 and 2024 from competitors pursuing IL7R and TSLP pathway inhibitors
Strictly private and confidential Multiple read outs expected in 2023 and 2024 from competitors pursuing IL7R and TSLP pathway inhibitors 13 Anti - IL7R Anti - TSLP Company Timing of readout Trial size Phase 3 Phase 2 Phase 1 n = 150 2023 2023 Expected initiation in 2022 n = 400 2024 n = 270 2023 n
Slide 14: Lead program
IL7 ZB 168 TSLP TSLPR IL7R α Lead program
Slide 15: Our lead program, ZB-168, a fully human IL7Rα antibody
Strictly private and confidential Our lead program, ZB - 168 15 ZB - 168, a fully human IL7R α antibody • Originally developed by Pfizer • IL7R α inhibition has potential to inhibit two critical immune pathways (IL7 and TSLP) • Potential applicability in broad range of T - cell mediated diseases and
Slide 16: Phase 1b trial in T1DM: design
Strictly private and confidential Phase 1b trial in T1DM : design 16 • Generally healthy adults within 2 years of clinical diagnosis of type 1 diabetes • Stably treated with insulin • HbA1c < 9% • 37 patients received study drug or placebo • 12 weeks of dosing every other week, or up to 11 weeks of
Slide 17: Phase 1b trial in T1DM: safety
Strictly private and confidential Phase 1b trial in T1DM: safety 17 Treatment - related AE incidence, n(%) AE, MedDRA version 19.1 ZB - 168 1 mg/kg Q2wk ZB - 168 3 mg/kg Q2wk ZB - 168 8 mg/kg Q2wk ZB - 168 6 mg/kg Qlwk Placebo preferred term (n = 8) (n= 9) (n = 8) (n= 5) (n = 7) Headache 2 (25.0) 2
Slide 18: Phase 1b trial in T1DM: pharmacodynamics
Strictly private and confidential Phase 1b trial in T1DM: pharmacodynamics 18 Unbound IL7R levels • Near complete pSTAT5 suppression achieved with doses of 3 mg/kg q2w, 6 mg/kg qw, and 8 mg/kg q2w • Doses >= 3mg/kg q2w achieved >90% receptor occupancy through treatment period Receptor occupancy (mea
Slide 19: Phase 1b trial in T1DM: pharmacodynamics, impact on key T-cell subpopulations
Strictly private and confidential Phase 1b trial in T1DM: pharmacodynamics 19 Impact on key T - cell subpopulations • Up to 70% reduction in CD8+ T effector memory cells • Similar reductions seen for naïve and central memory T - cells • Increases in ratios observed for all doses tested • ZB - 168 sh
Slide 20: Alopecia areata
Alopecia areata
Slide 21: Alopecia areata presents an attractive and accessible market
Strictly private and confidential Alopecia areata presents an attractive and accessible market 21 1.Alopecia areata; 2. Source: Medscape Demographics Est. figures US Population Age <10 years Scalp prosthesis should be considered in patients with >50% scalp involvement Alopecia areata Age >10 years M
Slide 22: Alopecia areata: a common autoimmune disease driven by T effector cells
Strictly private and confidential 22 Alopecia areata: a common autoimmune disease driven by Teffector cells • Invasion of T - cells into hair follicle (normally immune privileged) • Resulting inflammation impedes normal hair growth cycle • Importantly, inflammation does not destroy hair follicle • O
Slide 23: Strong mechanistic evidence to support key role for IL7 in alopecia
Strictly private and confidential 23 Strong mechanistic evidence to support key role for IL7 in alopecia 23 Generation of key translational skin graft model of AA 8 weeks of treatment with either anti IL7R or control antibodies Statistically significant regrowth of hair in treatment arm C3H/HeJ mous
Slide 24: Oral JAK inhibitors: effective but with meaningful safety risks
Strictly private and confidential 24 Oral JAK inhibitors: effective but with meaningful safety risks Primary endpoint achieved in baricitinib phase 3 studies 1 , FDA - approved, but… …safety concerns will persist 2 • Separation from placebo evident by week 16 • Only 20 - 40% of patients achieved pri
Slide 25: We are planning to initiate two phase 2 studies in 2023
Strictly private and confidential We are planning to initiate two phase 2 studies in 2023 25 2023 2024 2025 Alopecia areata POC trial CMC clinical supply Additional indications under consideration Lead Indication Additional indications Key experimental medicine studies 2022 Other development activit
Slide 26: Other indications under consideration
Strictly private and confidential Other indications under consideration 26 IL7: Type 1 diabetes mellitus Sjogren’s syndrome Ulcerative colitis TSLP: Asthma CSU CRSwNP
Slide 27: Transaction Summary
Strictly private and confidential 42.4% 35.8% 12.8% 9.0% Sources (million) Uses (million) SPAC Cash in Trust $139.4 Cash on Balance Sheet $174.4 Cash on Balance Sheet 0.0 Selling Shareholder Equity Rollover 165.0 Private Placement of Common Equity (PIPE) 50.0 Transaction Fees and Expenses 15.0 Selli
Slide 28: Risk Factors (1/3)
Strictly private and confidential 28 Risk Factors (1/3) The below list of risk factors has been prepared as part of the Proposed Business Combination. The risks presented below are cer tain of the general risks related to the business of the Company, JATT and the Proposed Business Combination and su
Slide 29: Risks related to the Company's financial position (continued)
Strictly private and confidential RISKS RELATED TO THE COMPANY’S FINANCIAL POSITION (continued) • We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be abl e to achieve or sustain profitability in the future. We have not generate
Slide 30: Risk Factors (3/3)
Strictly private and confidential 30 Risk Factors (3/3) RISKS RELATED TO THE COMPANY’S INTELLECTUAL PROPERTY AND TECHNOLOGY (continued) • Patent terms may be inadequate to protect our competitive position with respect to ZB - 168 for an adequate amount of time. • If we do not obtain patent term exte